Carcinomas harbouring NUT translocation are potentially treatable with selective bromodomain extra terminal (BET) inhibitors [14] which are available through ongoing phase I clinical trials (e.g. GSK525762 (NTC01587703) and TEN-010 (NCT01987362)). Here, NUTM1 is linked to carcinoma.